azomycin has been researched along with Carcinogenesis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahmed, M; Ba-Alawi, W; Beltran, H; Berlin, A; Boutros, PC; Bristow, RG; Chen, S; Ci, X; Ellis, L; Fazli, L; Feng, FY; Gleave, M; Guo, H; Haibe-Kains, B; He, HH; Hua, JT; Koritzinsky, M; Li, E; Liang, Y; Lin, D; Mahamud, O; Nguyen, T; Poirier, JT; Puca, L; Rudin, CM; Sheahan, AV; Soares, F; Su, P; Tsao, MS; van der Kwast, T; Vellanki, RN; Vosoughi, A; Wang, Y; Wouters, BG; Xu, J; Xu, X; Xue, H; Zhang, S; Zhang, Y; Zoubeidi, A | 1 |
1 other study(ies) available for azomycin and Carcinogenesis
Article | Year |
---|---|
ONECUT2 is a driver of neuroendocrine prostate cancer.
Topics: Animals; Carcinogenesis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Datasets as Topic; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neuroendocrine Tumors; Nitroimidazoles; Phosphoramide Mustards; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Signal Transduction; Smad3 Protein; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |